Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 489 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acne Clear all
Completed Phase 3 Interventional Results available

To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.

NCT02465632
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel, BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 4 Interventional Results available

Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris

NCT00835198
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone; Tretinoin, Tretinoin
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Strongsville, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2011 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Not applicable Interventional Results available

Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy

NCT01328080
View directory record Official record
Conditions
Acne Keloidalis Nuchae
Interventions
Targeted UV-B
Radiation
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 20, 2026, 10:12 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
61
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Not yet recruiting Not applicable Interventional

Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris

NCT06729450
View directory record Official record
Conditions
Acne Vulgaris on the Face
Interventions
DispersinB Acne Cleanser
Device
Lead sponsor
Kane Biotech Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional

Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne

NCT01106807
View directory record Official record
Conditions
Acne
Interventions
Epiduo vehicle gel, CD07223, Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 35 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Hot Springs, Arkansas • Louisville, Kentucky • Warren, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Not applicable Interventional

Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris

NCT03303170
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sebacia Microparticles, Nd:Yag Laser
Device
Lead sponsor
Sebacia, Inc.
Industry
Eligibility
12 Years to 45 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Scottsdale, Arizona • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

NCT03497897
View directory record Official record
Conditions
Inflammatory Acne
Interventions
LYS006 20 mg, LYS006 2 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Fremont, California • Santa Monica, California • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 20, 2026, 10:12 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Safety and Efficacy of Candela Technology

NCT06202274
View directory record Official record
Conditions
Hair Reduction, Tattoo Removal, Wrinkle, Acne, Scars, Benign Cutaneous Vascular Lesions, Skin Conditions
Interventions
Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE
Device
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
2
States / cities
Jacksonville, Florida • Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

NCT02267746
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene (Fabior™), Tazarotene (Actavis), Vehicle foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
14
States / cities
Encino, California • Fremont, California • Brandon, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Evaluating the Efficacy and Safety of Omnilux Clear on Mitigating Mild to Moderate Acne

NCT06936332
View directory record Official record
Conditions
Acne
Interventions
Omnilux Clear Light Emitting Diode Treatment
Device
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05620836
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
38
States / cities
Scottsdale, Arizona • Arkansas City, Arkansas • Fayetteville, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne

NCT01701024
View directory record Official record
Conditions
Acne
Interventions
ACYC, ACYC vehicle
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
24
States / cities
Mobile, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 4 Interventional Results available

Epiduo Pediatric Acne Study

NCT01138735
View directory record Official record
Conditions
Acne
Interventions
adapalene/benzoyl peroxide, Topical Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years to 11 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Santa Rosa, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

NCT01628549
View directory record Official record
Conditions
Acne Vulgaris
Interventions
50 mg P005672-HCl, Placebo, 100 mg P005672-HCl
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
12 Years to 45 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne

NCT00776919
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin / benzoyl peroxide gel, clindamycin gel, BPO gel, vehicle gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years to 45 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
San Diego, California • Santa Monica, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Not applicable Interventional Results available

Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles

NCT04057768
View directory record Official record
Conditions
Acne Scars - Mixed Atrophic and Hypertrophic, Wrinkle
Interventions
Venus Viva
Device
Lead sponsor
Venus Concept
Industry
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne

NCT02404285
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Next Science Acne Gel, Vehicle
Drug
Lead sponsor
Next Science TM
Industry
Eligibility
12 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Jacksonville, Florida • Ponte Vedra, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional

Microdermabrasion for Acne

NCT00355485
View directory record Official record
Conditions
Acne Vulgaris
Interventions
microdermabrasion
Device
Lead sponsor
University of Michigan
Other
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Subantimicrobial Doxycycline in Acne

NCT05399290
View directory record Official record
Conditions
Acne Vulgaris, Pediatrics
Interventions
Doxycycline Hyclate
Drug
Lead sponsor
Michigan State University
Other
Eligibility
13 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

NCT02965456
View directory record Official record
Conditions
Acne
Interventions
IDP 121 Lotion, IDP-121 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
34
States / cities
Glendale, Arizona • Rogers, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 4 Interventional Results available

A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris

NCT02032407
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone Gel
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 20, 2026, 10:12 PM EDT
Terminated Not applicable Interventional Results available

Laser Treatment of Moderate to Severe Acne Vulgaris

NCT04466527
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Laser Intervention
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

NCT00688064
View directory record Official record
Conditions
Severe Acne Vulgaris
Interventions
Adapalene BPO Gel associated with Doxycyline Hyclate, Vehicle Gel associated with Doxycycline Hyclate
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
28
States / cities
Oceanside, California • San Diego, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 20, 2026, 10:12 PM EDT